1Rajkumar S V, Witzig T E. A review of angiogenesis and antiangiogenie therapy with thalidomide in multiple myeloma [J].Cancer Treat Rev,2000,26:351 - 362.
2Rajkumar S V, Leong T, Roche P C, et al.Prognostic value of bone marrow angiogensis in multiple myeloma[J]. Clin Cancer Rev,2000,6:3111-3116.
3Singhal S, Mehta J, Eddlemon P ,et al.Marked anti-tumoreffect from anti-angiogenesis therapy with thalidomidein high risk refractory multiple myeIoma[J]. Blood,1998.98:318-322.
5Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory dervatives augment natural killer cell cytotoxicity in multiple myeloma. Blood ,2001,98:210.
6Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide:identi- fication of prognostic factors in a phase 2 study of 169 patients. Blood, 2001,98:492.
7Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood ,2001,96:2943.
8Singhal S, Mehta J, Desikan R, et al. Antitumoract activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999,341:1565-1571.
9张之南.血液病诊断与疗效标准2版[M].北京:科学出版社,1998.373-380.
10Davies FE;Raje N;Hideshima T.Thalidomide and immunomodu latory derivatives augment natural killer cell cytotoxicity in multiple myeloma[J],2001(01).
